Amedisys Announces Clinical Excellence in Speech Language Pathology
February 25 2015 - 2:00PM
Amedisys, Inc. (Nasdaq:AMED) today announced for the third year in
a row it has proven clinical excellence with its Speech-Language
Pathology (SLP) program as evidenced by the American
Speech-Language and Hearing Association (ASHA) National Outcomes
Measurement System (NOMS) report for 2014.
NOMS is a data collection system developed to illustrate the
value of Speech-Language Pathology services provided to patients
with swallowing deficits, cognitive and memory impairments, and
communication disorders. It is a recognized outcome data collection
system that is recognized by the Centers for Medicare and Medicaid
Services (CMS).
The key to NOMS is the use of ASHA's Functional Communication
Measures (FCMs). FCMs are a series of disorder specific seven-point
rating scales designed to describe the change in an individual's
functional communication, swallowing, or cognitive/memory abilities
over the course of treatment.
The 2014 data reflects the Amedisys Speech-Language Pathology
program exceeded the national industry average by 19.3% compared to
the healthcare industry for 2014. The national average for 2014 was
52.2% of treatment goals met in the home, while Amedisys met 71.5%
of treatment goals.
"We are extremely proud of our Speech-Language Pathology team
here at Amedisys for achieving this level of high quality care for
our patients," said Dr. David Hutchings, CCC-SLP.D., the Senior
Managing Director of Rehabilitation for Amedisys. "Helping our
patients recover their ability to swallow, remove feeding tubes,
and to improve communication and memory deficits is extremely
rewarding. Our team of 400 Speech-Language Pathologists across the
country is honored to work for an organization that values this
important healthcare practice," he concluded.
Amedisys' Speech-Language Pathology program has proven clinical
outcomes which include reduced risk of aspiration pneumonia;
increased ability to eat and swallow; reduced need for feeding
tubes; increased weight and nutrition status; improved ability to
communicate wants and needs; and enhanced memory and cognitive
functions or learned compensation techniques.
For more information about NOMS, please visit:
http://www.asha.org/members/research/noms/.
For more information about the Amedisys Speech-Language
Pathology program, please visit: www.Amedisys.com/SLP.
About Amedisys:
Amedisys, Inc. (Nasdaq:AMED) is a leading health care at home
company delivering personalized home health and hospice care to
approximately 360,000 patients each year. Amedisys is focused on
delivering the care that is best for our patients, whether that is
home-based recovery and rehabilitation after an operation or
injury, care focused on empowering them to manage a chronic
disease, palliative care for those with a terminal illness, or
hospice care at the end of life. The Company's state-of-the-art
advanced chronic care management programs and leading-edge
technology enables it to deliver quality care based upon the latest
evidence-based best practices. Amedisys is a recognized innovator,
being one of the first in the industry to equip its clinicians with
point-of-care laptop technology and referring physicians with an
internet portal that enables real-time coordination of patient care
seamlessly. Amedisys also has the industry's first-ever nationwide
Care Transitions program, designed to reduce unnecessary hospital
readmissions through patient and caregiver health coaching and care
coordination, which starts in the hospital and continues throughout
completion of the patient's home health plan of care. For more
information about the Company, please visit:
http://www.amedisys.com.
CONTACT: Kendra Kimmons
Managing Director of Communications
225-299-3708
kendra.kimmons@amedisys.com
Amedisys (NASDAQ:AMED)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amedisys (NASDAQ:AMED)
Historical Stock Chart
From Apr 2023 to Apr 2024